Willing to return to enrolling medical site for all study assessmentsXx_NEWLINE_xXWillingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purposeXx_NEWLINE_xXBe willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocolXx_NEWLINE_xXPatients with inability to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictionsXx_NEWLINE_xXWillingness to return to Mayo Clinic for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXAble to return for treatment and follow-up on the specified daysXx_NEWLINE_xXWilling to return to enrolling institution for follow-up or have a local physician willing to submit response and outcome data; Note: any and all therapy, potentially in its entirety, may be conducted outside of the Mayo ClinicXx_NEWLINE_xXMust be willing to return to Mayo Clinic enrolling institution for follow-up.Xx_NEWLINE_xXWillingness to return to enrolling institution for follow-upXx_NEWLINE_xXPatients with inability to return for follow-up visits to assess toxicity to therapyXx_NEWLINE_xXPatients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy will be excludedXx_NEWLINE_xXPatients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester or another participating institution for follow-up; patients who are randomized to Arm B (cytotoxic chemotherapy) may receive chemotherapy at any oncology clinic able to provide the protocol-directed therapy and willing to send laboratory data to the participating institution; however, patients must be willing to return to the participating institution every two months for evaluation; patients who are randomized to Arm A must be willing to receive all treatment and follow-up at a participating institutionXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXPatients must be willing to receive follow-up care for a minimum of five years after treatment at the treating institution, including annual follow up visits; in the event that the patient is not from the local area and returning to the treating institution for follow up visits is too difficult, they must be willing to have their outside medical information (i.e. imaging studies, laboratory results and doctor or other health professional notes) released to the treating institution to track the results of treatmentXx_NEWLINE_xXPatients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXAbility to attend required study visits and return for adequate follow up, as required by this protocolXx_NEWLINE_xXWilling to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)Xx_NEWLINE_xXPatients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up during active monitoring phase of the studyXx_NEWLINE_xXWilling to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up for a minimum of 1 yearXx_NEWLINE_xXWillingness to return to Mayo Clinic in Rochester, Minnesota for follow-upXx_NEWLINE_xXPatients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy; telemedicine visits are acceptableXx_NEWLINE_xXWilling to return to enrolling institution for follow-up during the Active Monitoring phase of the study\r\n* Note: the Active Monitoring phase of a study includes active treatment and observationXx_NEWLINE_xXWilling to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)Xx_NEWLINE_xXPatient is willing to undergo treatment and monitoring at the enrolling institutionXx_NEWLINE_xXWillingness to return to Mayo Clinic in Rochester, Minnesota for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institutionXx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXAbility to return to Duke University Medical Center for adequate follow-up, as required by this protocolXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study [i.e. active treatment and observation])Xx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXWillingness to return to the enrolling medical site for all study assessmentsXx_NEWLINE_xXWilling to return to Mayo Clinic for follow-upXx_NEWLINE_xXWillingness to return to the Mayo Clinic enrolling institution for follow-upXx_NEWLINE_xXWilling to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXWilling to return for all required study assessmentsXx_NEWLINE_xXWilling to return to Mayo Clinic enrolling institution for follow-upXx_NEWLINE_xXPatients must be willing to receive follow-up care for a minimum of 5 years after treatment at participating institution(s) and annual visits unless it is too difficult to return to participating institution for follow-up care; in that event, patients must be willing to have outside medical information released in order to track the results of treatmentXx_NEWLINE_xXPatients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictionsXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXAble to return for treatment and follow-up as specified in the protocolXx_NEWLINE_xXAbility to attend required study visits and return for adequate follow-up, as required by this protocol.Xx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to Mayo Clinic enrolling institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to enrolling institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to Mayo Clinic in Rochester, Minnesota for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the treatment and observation phases of the study)Xx_NEWLINE_xXPatients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictionsXx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXPatients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWillingness to return to Mayo Clinic enrolling institution for follow-upXx_NEWLINE_xXARM A: Willingness to return to Mayo Clinic in Arizona for follow-upXx_NEWLINE_xXARM B: Willingness to return to Mayo Clinic in Arizona for follow-upXx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow upXx_NEWLINE_xXWillingness to return to enrolling institution for follow upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXPatients must be willing to return to the clinic for follow-up visitsXx_NEWLINE_xXWilling to return to Mayo clinic for follow upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuationXx_NEWLINE_xXWilling to return to participating medical institutions for follow-upXx_NEWLINE_xXWilling to return to Mayo Clinic for follow upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to Mayo Clinic for follow upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (active monitoring phase of the study); Note: During the active monitoring phase of a study (i.e., active treatment), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXAbility to attend required study visits and return for adequate follow up, as required by this protocolXx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXAgree to return for all follow-up evaluations and procedures specified in the protocolXx_NEWLINE_xXWilling and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to consenting Mayo Clinic (Mayo Clinic’s campus in Rochester), for follow-up during the Active Monitoring Phase of the studyXx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXPatients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictionsXx_NEWLINE_xXWilling to return to consenting institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXPatients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-up appointmentsXx_NEWLINE_xXWillingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-upXx_NEWLINE_xXSubjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWilling to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to Mayo Clinic Rochester, Mayo Clinic Arizona, Mayo Clinic Florida for treatment\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to consenting Mayo Clinic (Mayo Clinic’s campus in Rochester, Mayo Clinic’s campus in Arizona, or Mayo Clinic’s campus in Florida) institution for follow-up during the active monitoring phase of the studyXx_NEWLINE_xXWilling to return to Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-upXx_NEWLINE_xXAbility to return to Duke University Medical Center for adequate follow-up as required by this protocolXx_NEWLINE_xXWilling to return to consenting Mayo Clinic institution for follow-up during the Active Monitoring Phase of the study; Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-up, except for some appointments that can be made with the local physicianXx_NEWLINE_xXWillingness to return to Mayo ClinicXx_NEWLINE_xXAbility to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requiresXx_NEWLINE_xXThe subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.Xx_NEWLINE_xXWillingness to return to Mayo Clinic Rochester for follow-upXx_NEWLINE_xXInability to return for follow-up visits or obtain follow-up studies required to assess toxicity and response to therapyXx_NEWLINE_xXWilling to return to Mayo Clinic, Rochester during the observation phaseXx_NEWLINE_xXPatients who are unable to return for follow-up visits as required by this studyXx_NEWLINE_xXWillingness to return to a lymphoma Specialized Program of Research Excellence (SPORE) enrolling institution for follow-upXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictionsXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictionsXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWillingness to return to Mayo Clinic for follow upXx_NEWLINE_xXAgreement to return for the trial required follow-up visitsXx_NEWLINE_xXWilling to return to Mayo Clinic enrolling institution for follow-upXx_NEWLINE_xXWilling to return to consenting institution for follow-up during the studyXx_NEWLINE_xXWilling to return to enrolling institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution (Mayo Clinic in Arizona) for follow-up and all study treatmentsXx_NEWLINE_xXPatients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapyXx_NEWLINE_xXWilling to return to Alliance enrolling institution for follow-upXx_NEWLINE_xXWillingness to return to the Alliance enrolling institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXWillingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to an Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-up (i.e., active monitoring, which includes active treatment and observation)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXAfter the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visitXx_NEWLINE_xXWilling to return to enrolling institution for follow-up of the study and optional crossover (if applicable)Xx_NEWLINE_xXWilling to return to an Alliance enrolling institution for follow-upXx_NEWLINE_xXWilling to work with the enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)Xx_NEWLINE_xXPatient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)Xx_NEWLINE_xXWillingness to return to the enrolling institution for follow-upXx_NEWLINE_xXWilling to return mail-in questionnaires during the observation phase of the studyXx_NEWLINE_xXWilling to use and return the technology provided by the studyXx_NEWLINE_xXWilling to undergo monthly follow-up assessment, either in person at the enrolling institution or by telephoneXx_NEWLINE_xXWillingness to return to the enrolling site for the study surgical procedures, including pre-operative and post-operative care; (patients in the ISDO arm must be willing to return to the enrolling site for yearly ovarian cancer assessment)Xx_NEWLINE_xXAgrees to return to participating institution for 3 HPV vaccine injectionsXx_NEWLINE_xXUnable to return for follow-up visits and testsXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)Xx_NEWLINE_xXSubjects, who, in the opinion of the clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-up visitsXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study; patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institutionXx_NEWLINE_xXWillingness to return to the enrolling site for ovarian cancer screening during the study periodXx_NEWLINE_xXReturn for follow-up visitsXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXWilling to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-upXx_NEWLINE_xXPatients must be willing to return to National Institutes of Health (NIH) for follow-upXx_NEWLINE_xX